Search

Purpose: Preserflo Microshunt surgery is a new surgical procedure in the management of glaucoma. We evaluated the effectiveness and safety of Preserflo Microshunt surgery throughout the first 6 months postoperatively, by comparing intraocular pressure (IOP), number of drop agents pre and post operatively and any registered complications. Methods: A case series of 30 patients with primary open angle glaucoma underwent Preserflo Microshunt surgery at a District General Hospital in the UK. Surgical technique included scleral application of Mitomycin C 0.4 mg/mL for 3 minutes prior to microshunt insertion. Patients had their intra ocular pressure recorded pre operatively, day 1, week 2, month 2 and after 6 months. The number of therapeutic agents in their glaucoma drops was also compared pre‐operatively and after 6 months. Results: Mean IOP was reduced form 17.4 mmHg at baseline to 8.9 mmHg at 2 months and 11.6 mmHg at 6 months. The mean number of drug agents reduced from 2.25 to 0.07, and a total of 28 out of 30 (93.3%) remained drop free at 6 months. There were three cases where patients required needling of the bleb, two subsequently required repositioning of the shunt, and an IOP spike at day one post operatively in one case. Conclusions: Early results for Preserflo Microshunt surgery show sustained reduction in IOP at 6 months, with the majority of patients requiring no glaucoma drops postoperatively. The surgery has been well tolerated by patients with less intense follow up compared to a traditional trabeculectomy and low complication rates. [ABSTRACT FROM AUTHOR]